CSIMarket Company Name, Ticker, Competitors, else..
 

Immunogen inc   (NASDAQ: IMGN)

Immunogen Inc 's

Competitiveness



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 

IMGN Sales vs. its Competitors Q3 2023


Comparing the current results to its competitors, Immunogen Inc reported Revenue increase in the 3 quarter 2023 by 637.72 % year on year.
The sales growth was above Immunogen Inc 's competitors' average revenue growth of 115.92 %, achieved in the same quarter.

• List of IMGN Competitors

With a net margin of 27.11 % Immunogen Inc achieved higher profitability than its competitors.

• More on IMGN Profitability Comparisons



Revenue Growth Comparisons




Net Income Comparison

Immunogen inc achieved net profit of $30.75 millions compared to a net loss of $-77.76 millions recorded in the same quarter a year ago.

<<  IMGN Stock Performance Comparisons





  

Overall company Market Share Q3 2023
Due to outstanding performance in Overall company, revenue grew by 637.72 % Immunogen inc improved its market share, to approximately 15.78 %.




<<  More on IMGN Market Share.
 
*Market share is calculated based on total revenue.





Publicly Traded Peers of Immunogen inc




Spyre Therapeutics Inc
Share Performance



+427.65%
One Year
Spyre Therapeutics Inc
Profile

Spyre Therapeutics develops long-acting antibody therapies targeting inflammatory bowel and rheumatic diseases.

More about Spyre Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ - mill. $ - mill. $ -178.918 mill.


Erasca Inc
Share Performance



+296.94%
This Year
Erasca Inc
Profile

Erasca Inc is a biotechnology company that focuses on discovering and developing innovative therapies for cancer. Their business model revolves around leveraging cutting-edge technologies and scientific expertise to identify and advance multiple drug candidates simultaneously. By collaborating with academic institutions and biopharmaceutical partners, Erasca aims to accelerate the development of cancer treatments to improve patient outcomes.

More about Erasca Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 4,436.549 mill. $ - mill. $ -287.223 mill.


Rain Enhancement Technologies Holdco Inc
Share Performance



-80.01%
This Year
Rain Enhancement Technologies Holdco Inc
Profile

Rain Therapeutics Inc is a biopharmaceutical company that focuses on discovering and developing precision oncology therapies. Their business model revolves around identifying genetic alterations and biomarkers in cancer patients, and then developing targeted therapies to address these specific alterations. By tailoring treatments to individual patients, they aim to improve outcomes and provide more effective and personalized cancer care.

More about Rain Enhancement Technologies Holdco Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ - mill. $ - mill. $ -11.763 mill.


Dar Bioscience Inc
Share Performance



+3.26%
30 Days
Dar Bioscience Inc
Profile

Dar Bioscience Inc. is a biopharmaceutical company that focuses on developing and commercializing innovative products for women's health. Their business model revolves around the identification of promising product candidates, conducting clinical trials to validate their safety and efficacy, and then seeking regulatory approvals and partnerships for commercialization. By addressing unmet needs in women's health, Dar Bioscience aims to improve the quality of life for women worldwide while generating revenue through product sales and collaborations.

More about Dar Bioscience Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 11.547 mill. $ 1.345 mill. $ -10.987 mill.


Trevi Therapeutics Inc
Share Performance



-19.59%
30 Days
Trevi Therapeutics Inc
Profile

Trevi Therapeutics Inc is a biopharmaceutical company that specializes in developing therapies for neurologically mediated conditions. Their business model focuses on identifying and developing innovative treatment options that target specific receptors in the nervous system. By leveraging their expertise in neuroscience and drug development, Trevi aims to bring novel therapies to market and improve the lives of patients suffering from these conditions.

More about Trevi Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2,256.637 mill. $ - mill. $ -51.107 mill.

63 more competitors available

Sign in to see all competitors

Sign In Create Free Account

Sources: Immunogen inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Immunogen inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.